Continuous therapy in myeloma – the future
Myeloma – upfront and RRMM
CLL – heading for a cure?
High risk and resistant CML: new diagnostic tools and treatment approaches
Myeloproliferative neoplasms – current thinking
Workshop: AML

ECHELON 1 : Brentuximab should be used first line in advanced Hodgkin lymphoma
GALLIUM : Obinutuzumab, not rituximab, should be used first line for patients with symptomatic follicular lymphoma